MDLinxA Staffing Issue Delayed a Deadly Lung Cancer Diagnosis for at Least One Veteran

Systematic Oversight in Veteran Healthcare: A Case Study of Omaha VA’s Lung Imaging Registry Failure and Its Broader Implications

In a sobering revelation, the Omaha VA Medical Center’s lapse in monitoring its lung imaging registry has brought to light critical gaps in patient follow-up protocols. This detailed account underscores the potentially grave consequences of administrative oversights in healthcare settings, particularly for veterans requiring diligent medical surveillance. As we dissect this incident, the aim is to glean insights that can fortify medical vigilance and patient care continuity, thereby preventing similar failures in the future.

Key Points:

• The Omaha VA Medical Center’s lung imaging registry, designed to flag abnormalities for follow-up, was unmonitored for over a year between 2019 and 2021, leading to undetected and escalating health issues in patients.
• Vietnam veteran Micheal Hansen’s case exemplifies the tragic outcomes of this oversight. A 2 cm lung mass identified in 2019 was not followed up, resulting in the mass nearly quadrupling in size and progressing to stage IV lung cancer by October 2020.
• Hansen’s family filed a lawsuit against the Omaha VA in September 2021, citing medical negligence and failure to warn, to which the VA did not object.
• The registry oversight occurred following the retirement of the nurse in charge in 2019, with the position left vacant due to delays in hiring someone with advanced qualifications.
• Despite awareness of the gap in registry monitoring, no effective interim measures were taken, leading to potentially more undetected cases.
• The VA acknowledged the error but disputed the extent of damages, citing Hansen’s medical complexity and lifestyle factors as contributors to his condition.
• Lisa Hansen’s legal team, representing the late Micheal Hansen, sought not only damages but also clarity on the extent of similar oversight cases and measures for future prevention.
• A tentative settlement was reached in December 2023, but the details, including the settlement amount, remain undisclosed.

According to the American Cancer Society, the 5-year survival rate for lung cancer when diagnosed at an early stage (localized) is approximately 59%, but only about 16% for cancers that have spread to distant parts of the body.

More Legal Matters